Eur Rev Med Pharmacol Sci 2022; 26 (22): 8206-8208
DOI: 10.26355/eurrev_202211_30351

Comment on: Comparative dissolution profiles of two anti-emetic delayed-release dosage forms of doxylamine and pyridoxine: Xonvea® tablets vs. Cariban® capsules

K. Urso, P. Saz-Leal, L. Zamorano Dominguez, M. Mangrella

ITF Research Pharma S.L.U. Alcobendas, Spain. k.urso@italfarmacogroup.com

Free PDF Download

To cite this article

K. Urso, P. Saz-Leal, L. Zamorano Dominguez, M. Mangrella
Comment on: Comparative dissolution profiles of two anti-emetic delayed-release dosage forms of doxylamine and pyridoxine: Xonvea® tablets vs. Cariban® capsules

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 22
Pages: 8206-8208
DOI: 10.26355/eurrev_202211_30351

Keywords Related articles:

  1. Comparative dissolution profiles of two anti-emetic delayed release dosage forms of doxylamine and pyridoxine: Xonvea® tablets vs. Cariban® capsules
  2. Midazolam as an anti-emetic
  3. Efficacy of intratumoral chemotherapy using arsenic trioxide (As2O3) sustained release tablets for the treatment of neurogliocytoma in nude mice
  4. Comparative analysis of the use of non-steroidal anti-inflammatory drugs in Montenegro, Finland and Croatia in the period 2010-2019
  5. Comment on safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis